Article: In vitro activity of HR 810, a new broad-spectrum cephalosporin

HR 810, 3-[(2,3-cyclopenteno-1-pyridinium)methyl]-7-[2-syn-methoximino-2-(2-aminothiazole-4-yl)-acetamido] ceph-3-em-4-carboxylate, is a new semisynthetic cephalosporin derivative. The in vitro activity of HR 810 was compared with that of cefotaxime, ceftazidime, piperacillin and gentamicin using 368 strains of gram-negative and gram-positive bacteria. HR 810 was highly active against Enterobacteriaceae, being the most active of the cephalosporins against Enterobacter, Serratia and Citrobacter spp.; the MICs ranged from much less than 0.06 to 8 mg/l. The activity of HR 810 against Pseudomonas aeruginosa and Acinetobacter spp. was almost as good as that of ceftazidime. The new compound was superior to the other cephalosporins against Staphylococcus aureus and inhibited all Streptococcus faecalis strains at a concentration of 16 mg/l.

Citing Articles

The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.

Turner J, Muraoka A, Bedenbaugh M, Childress B, Pernot L, Wiencek M Front Microbiol. 2022; 13:807955.

PMID: 35401470 PMC: 8988990. DOI: 10.3389/fmicb.2022.807955.

In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Jones R, Thornsberry C, Barry A Antimicrob Agents Chemother. 1984; 25(6):710-8.

PMID: 6611135 PMC: 185628. DOI: 10.1128/AAC.25.6.710.

In vitro activity of HR 810, a new cephalosporin.

Bertram M, Bruckner D, Young L Antimicrob Agents Chemother. 1984; 26(2):277-9.

PMID: 6593000 PMC: 284139. DOI: 10.1128/AAC.26.2.277.

In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents.

Wise R, Cross C, Andrews J Antimicrob Agents Chemother. 1984; 26(6):876-80.

PMID: 6524904 PMC: 180042. DOI: 10.1128/AAC.26.6.876.

Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Jones R, Thornsberry C, Barry A, Ayers L, Brown S, Daniel J J Clin Microbiol. 1984; 20(3):409-12.

PMID: 6490826 PMC: 271340. DOI: 10.1128/jcm.20.3.409-412.1984.

References

1.

Preheim L, PENN R, Sanders C, Goering R, Giger D . Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 1982; 22(6):1037-41. PMC: 185717. DOI: 10.1128/AAC.22.6.1037. View

2.

Cullmann W, Opferkuch W, Stieglitz M . Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime. Eur J Clin Microbiol. 1983; 2(4):350-2. DOI: 10.1007/BF02019466. View

3.

Platt R, EHRLICH S, Afarian J, OBrien T, Pennington J, KASS E . Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother. 1981; 20(3):351-5. PMC: 181699. DOI: 10.1128/AAC.20.3.351. View

4.

Bauernfeind A . Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810. Eur J Clin Microbiol. 1983; 2(4):354-5. DOI: 10.1007/BF02019468. View

5.

Wiedemann B . HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase. Eur J Clin Microbiol. 1983; 2(4):352-4. DOI: 10.1007/BF02019467. View

In Vitro Activity of HR 810, a New Broad-spectrum Cephalosporin